Ye Tian

Dr. Ye Tian


Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2023 in Hepatology
Verified
Journal Article
Closed access
YTYe Tian
Ye Tian
MJMatthew J. Jellinek
Matthew J. Jellinek
KMKritika Mehta
Kritika Mehta
SSSun Mi Seok
Sun Mi Seok
SKShanny H. Kuo
Shanny H. Kuo
BWBo Wang
Bo Wang
Background and Aims: NASH, characterized by inflammation and fibrosis, is emerging as a leading etiology of HCC. Lipidomics analyses in the liver have shown that the levels of polyunsaturated phosphatidylcholine (PC) are decreased in patients with NASH, but the roles of membrane PC composition in the pathogenesis of NASH have not been investigated. Lysophosphatidylcholine acyltransferase 3 (LPCAT3), a phospholipid (PL) remodeling enzyme that produces polyunsaturated PLs, is a major determinant of membrane PC content in the liver. Approach and Results: The expression of LPCAT3 and the correlation between its expression and NASH severity were analyzed in human patient samples. We examined the effect of Lpcat3 deficiency on NASH progression using Lpcat3 liver-specific knockout (LKO) mice. RNA sequencing, lipidomics, and metabolomics were performed in liver samples. Primary hepatocytes and hepatic cell lines were used for in vitro analyses. We showed that LPCAT3 was dramatically suppressed in human NASH livers, and its expression was inversely correlated with NAFLD activity score and fibrosis stage. Loss of Lpcat3 in mouse liver promotes both spontaneous and diet-induced NASH/HCC. Mechanistically, Lpcat3 deficiency enhances reactive oxygen species production due to impaired mitochondrial homeostasis. Loss of Lpcat3 increases inner mitochondrial membrane PL saturation and elevates stress-induced autophagy, resulting in reduced mitochondrial content and increased fragmentation. Furthermore, overexpression of Lpcat3 in the liver ameliorates inflammation and fibrosis of NASH. Conclusions: These results demonstrate that membrane PL composition modulates the progression of NASH and that manipulating LPCAT3 expression could be an effective therapeutic for NASH.

10 September 2001 in Cereal Chemistry
Verified
Journal Article
Closed access
PDF file
YTYe Tian
Ye Tian
PBP. Buriak
P. Buriak
SES. R. Eckhoff
S. R. Eckhoff

24 April 2026 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
WLWei Lu
Wei Lu
ZZZhiming Zhao
Zhiming Zhao
DMDonald Molina
Donald Molina
HFHuaxun Fan
Huaxun Fan
RSRuicheng Shi
Ruicheng Shi
BWBo Wang
Bo Wang
The liver plays a critical role in lipid homeostasis, where lipids are either secreted as very-low-density lipoproteins (VLDL) or stored in lipid droplets (LDs). However, the regulatory mechanisms governing these two interconnected processes remain poorly understood. Here, we demonstrate that SEC16B functions as a lipid-responsive regulator in the liver, promoting VLDL secretion and LD expansion to handle lipid flux and maintain lipid homeostasis. Genome-wide association studies have identified single-nucleotide polymorphisms in SEC16B to be highly associated with serum lipid levels in humans. Hepatic Sec16b deficiency decreases serum lipid levels by impairing VLDL secretion through mechanisms that are at least partially independent of microsomal triglyceride transfer protein (MTP)-mediated ApoB lipidation and COPII-mediated intracellular trafficking. SEC16B partially localizes at ER-LD contact sites and promotes LD expansion by facilitating the targeting of ER proteins to LDs. More importantly, suppression of Sec16b dramatically lowers serum lipid levels and reduces atherosclerotic lesion size in Ldlr null mice. These data reveal a mechanism that coordinates VLDL and LD metabolism and suggest SEC16B as a potential therapeutic target for atherosclerosis treatment.

12 November 2022 in Journal of Case Reports and Images in Oncology
Verified
Journal Article
Open access
PDF file
VAVinay Ayyappan
Vinay Ayyappan
NSNichole Smith
Nichole Smith
YTYe Tian
Ye Tian
JMJean Miller
Jean Miller
Introduction: Post-transplant lymphoproliferative disorders (PTLD) are a complication of immunosuppression following organ transplantation. Due to their heterogeneous presentation, diagnosis of PTLD can be challenging. Case Report: In this case report, we present a patient with metastatic colon cancer, with remote history of multivisceral organ transplant 20-years prior, who presented with altered mental status and was diagnosed with primary central nervous system PTLD. Conclusion: This case illustrates the importance of continued suspicion of PTLD long after transplantation in solid-organ transplant recipients, even in the setting of multiple comorbidities.